Effect of Different Skin Creams on TEWL
Trial ID or NCT#
Status
Purpose
Prospective, single center, clinical pilot study to test the hypothesis that lipid rich EpiCeram® is superior in improving skin barrier function compared to Aveeno Daily Moisturising Sheer Hydration Lotion®.
Official Title
Comparison of Two Different Skin Creams and Their Effect on Transepidermal Water Loss (TEWL) in Pediatric and Adult Patients With Atopic Dermatitis: A Pilot Study
Eligibility Criteria
- 1. Parent guardian must be able to understand and provide informed consent per Institutional Review Board (IRB) guidelines and regulations.2. Male or female participants, between the ages of 0 to 40 years will be included3. Diagnosis of moderate to severe active AD (Scoring Atopic Dermatitis (SCORAD) score \> 26) without a history or current manifestations of eczema herpeticum (EH)4. AD affecting at least 3 different skin areas (contralateral arms and one lower extremity)
- 1. Inability or unwillingness of a parent guardian to give written informed consent, or to comply with study protocol.2. Participants with skin disease other than AD that might compromise the stratum corneum barriers (e.g., bullous diseases, psoriasis, cutaneous T-cell lymphoma (also called Mycosis Fungoides or Sezary syndrome\], dermatitis herpetiformis, Hailey-Hailey, or Darier's disease).3. Known or suspected immunosuppression4. Severe concomitant illness(es)5. History of serious life-threatening reaction to latex, tape, or adhesives6. Has received total body phototherapy (e.g., ultraviolet light B \[UVB\], psoralen ultraviolet light A \[PUVA\], tanning beds \[\>1 visit per week\]) within 30 days of the Enrollment Visit7. Use of topical corticosteroids, topical immunomodulatory agents (such as calcineural inhibitors and crisaborole), or topical antibiotics on the upper or lower extremities within 7 days of the Enrollment Visit8. Has taken a bleach bath within 7 days of the Enrollment Visit9. Use of systemic antibiotics, antiparasitics, antivirals, or antifungals within 7 days of the Enrollment Visit.
Investigator(s)
View on ClinicalTrials.gov